Allogenic stem cell transplantation in children and adolescents with acute lymphoblastic leukaemia - FORUMincluding the Add-on Study: A Phase II Study of Blincyto in Children with CD19+ Precursor B-lineage ALL and MRD-Positivity before and/or following first allogeneic HSCT - ALL SCT ped FORUM

St. Anna Kinderkrebsforschung0 个研究点目标入组 1,200 人开始时间: 2021年6月4日最近更新: 2021年10月8日

适应症

试验速览

暂无简介。

•All patients with ALL (except for patients with mature B-ALL) who fulfil the following criteria:
•age at time of diagnosis less or equal 18 years; at time of HSCT less or equal 21 years
•indication for allogeneic HSCT
•complete remission (CR) before SCT
•written consent of the parents (legal guardian) and, if necessary, the minor patient via Informed Consent Form”
•no pregnancy
•no secondary malignancy
•no previous HSCT
•HSCT is performed in a study participating centre
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 1000
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Patients who do not fulfil the inclusion criteria
•Non Hodgkin-Lymphoma
•The whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian
•No consent is given for saving and propagation of anonymous medical data for study reasons
•Severe concomitant disease that does not allow treatment according to the protocol at the investigator’s discretion: e.g. malformation syndromes, cardiac malformations, metabolic disorders; Renal impairment (< 30% of normal glomerular filtration rate), Severe pulmonary, hepatic or cardiac impairment due to toxicity or infection.
•Karnofsky / Lansky score < 50%
•Subjects unwilling or unable to comply with the study procedures

发起方